BioSpace News Archive

AlzeCure Pharma AB, a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, announced that the company has received positive results from the first clinical study with ACD856, aiming to evaluate half-life in humans.

California’s top-ranked district in science performance will implement STEMscopes digital curricula built on CA NGSS and aligned to California Science Framework

VBL Therapeutics, announced new data implicating the potential of its proprietary anti-MOSPD2 antibodies for treatment of rheumatoid arthritis.

Apellis Pharmaceuticals, Inc., a global biopharmaceutical company pioneering targeted C3 therapies, announced that the company will present at the Goldman Sachs 41st Annual Global Healthcare Conference on Thursday, June 11, 2020 at 1:20 p.m. ET.

Myriad Genetics, Inc., a global leader in molecular diagnostics and precision medicine, announced the publication of a prospective study demonstrating that the EndoPredict® test predicts which patients with ER+, HER2- early-stage breast cancer will benefit from neoadjuvant therapy.

Amicus Therapeutics announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference, being held virtually on Wednesday, June 10, 2020 at 8:00 a.m. ET.

Microbix Biosystems Inc., an award-winning life sciences innovator and exporter, announces the appointment of Alpha-Tec Systems, Inc., a Calibre Scientific Inc. firm, as distributor of its Quality Assessment Products for the United States.

CareDx, Inc., a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced the company will be participating in the upcoming Goldman Sachs Global Healthcare Conference.

The 48-week Phase 2b/3 study ANAVEX®2-73-AD-004 of ANAVEX®2-73 using biomarker and precision medicine in 450 patients with early Alzheimer’s disease is ongoing and currently over 50% enrolled.

Mereo BioPharma Group plc announces the completion of a $70 million private placement with a number of new and existing U.S based institutional and accredited investors.